ZENITHDRUG (ZENITHDRUG) fundamentals
ZENITHDRUG is a listed company, part of the Pharmaceuticals sector, listed on the NSE as ZENITHDRUG (ISIN INE0QWN01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What ZENITHDRUG does
Zenith Drugs Ltd is an India-based pharmaceutical company. The Company is mainly engaged in the business of manufacturing and trading of medicine. The Company offers a range of formulations in various forms, such as ORS powder, liquid oral, ointments, creams, gels and liquid externals, capsules, tablets. Its liquid oral products include Aceclofenac & Paracetamol Suspension; Albendazole Oral Suspension BP 25 mg/ml; Ambroxol Hydrochloride & Levocetirizine Dihydrochloride Syrup; Bromhexine Hydrochloride Syrup 4mg/5ml; Cetirizine Dihydrochloride and AmbroxolHydrochloride Syrup; Cetirizine Dihydrochloride and AmbroxolHydrochloride Syrup; Chlorphenamine, Ammonium Chloride and Sodium Citrate Syrup; Chlorpheniramine Maleate Oral Solution USP 2 mg / 5 ml, and others. Its ointment products include Cetrimide Cream BP 0.5% w/w, Chloroxylenol Cream 0.8% w/w, Ciprofloxacin Cream 0.5% w/w, Ciprofloxacin with Fluocinolone & Clotrimazole Cream and others.
Valuation and market data
| Last close | ₹46.35 |
|---|---|
| Market capitalisation | ₹79 crore |
| Enterprise value | ₹92 crore |
| P/E (TTM) | 0.22 |
| Price to book | 1.14 |
| Price to sales (TTM) | 0.17 |
| Book value per share | ₹40.50 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹176 crore | ₹6 crore | ₹4 crore | 0.00 |
| Mar 2025 | ₹136 crore | ₹9 crore | ₹7 crore | 4.18 |
| Mar 2024 | ₹134 crore | ₹13 crore | ₹10 crore | 5.56 |
| Mar 2023 | ₹116 crore | ₹7 crore | ₹5 crore | 122.03 |
| Mar 2022 | ₹93 crore | ₹4 crore | ₹3 crore | 80.32 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 70.0% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 30.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.